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The role of dopamine agonist treatment in corticotroph pitu-
itary tumors is controversial. The aim of this study was to
evaluate D2 receptor expression in 20 corticotroph pituitary
tumors and to correlate it to the in vitro effect of dopamine
agonists onACTHsecretionand the in vivoeffect of short-term
cabergoline treatment on cortisol secretion. D2 expression
was evaluated by receptor-ligand binding, immunohisto-
chemistry, and RT-PCR. A 50% or more decrease in daily uri-
nary cortisol levels was considered a significant clinical re-
sponse. At receptor-ligand binding, specific binding of
[125I]epidepride was found in 80% of cases. At immunohisto-
chemistry, specific D2 immunostaining was found in 75% of
cases. D2 expressionwas found in 83.3% of cases (D2long in 40%,
D2short in 20%, andboth in 40%) byRT-PCR. Significant in vitro
inhibition of ACTH secretionwas found in 100% of D2-positive
cases, but not in 100% of D2-negative cases by either bro-
mocriptine or cabergoline. A significant in vivo inhibition of
cortisol secretion after 3-month cabergoline treatment was
found in 60%, although a normalization of cortisol secretion
was found in 40% of cases. All cabergoline-responsive cases
were associated with D2 expression, whereas all noncabergo-
line-responsive cases but one were not associated with D2
expression. In conclusion, functional D2 receptors were ex-
pressed in approximately 80% of corticotroph pituitary tu-
mors. The effectiveness of cabergoline in normalizing cortisol
secretion in 40% of cases supports its therapeutic use in the
management of Cushing’s disease. (J Clin Endocrinol Metab
89: 2452–2462, 2004)
DOPAMINE IS THE predominant catecholamine neu-rotransmitter in the human central nervous system
where it controls a variety of functions, including cognition,
emotion, locomotor activity, and regulation of the endocrine
system (1). Dopamine also plays multiple roles in the pe-
riphery as a modulator of cardiovascular and renal function,
gastrointestinal motility, and hormone synthesis and secre-
tion (1). The various actions of dopamine are mediated by
five specific receptors (D1–D5), which can be subdivided into
two different receptor families on the basis of their biochemical
and pharmacological characteristics: D1-like, including D1 and
D5, and D2-like, including D2, D3, and D4 receptors (1). The
different dopamine receptor (DR) subtypes have different dis-
tributions and play different roles in the various organs and
tissues (1).
D2 receptor is expressed in the anterior and intermediate
lobes of the pituitary gland (2, 3), where it mediates the tonic
inhibitory control of hypothalamic dopamine on prolactin
(PRL) and MSH secretion, respectively (4–6). The presence
of a functional D2 receptor on tumor PRL-secreting cells
(7–10) led to a major therapeutic application in the treatment
of PRL-secreting pituitary tumors. Indeed, medical therapy
with dopamine agonists represents the first choice treatment
of this type of pituitary tumors, being effective in suppress-
ingPRLsecretion and inducing tumor shrinkage (11–13).More-
over, among thedifferent dopamine agonists, themore recently
developed drug, cabergoline, has been demonstrated to be
more effective than themost widely used drug, bromocriptine,
in the treatment of PRL-secreting pituitary tumors (14, 15).
Treatment with bromocriptine has been also investigated
in ACTH-secreting or corticotroph pituitary tumors, al-
thoughwith controversial results (12, 16).However, no study
has ever evaluated DR expression and the effect of caber-
goline treatment in controlling the ACTH and cortisol hy-
persecretion associated with corticotroph pituitary tumors.
The current study was designed with a 2-fold purpose: 1)
to evaluate DR expression in corticotroph pituitary tumors
by different techniques, namely receptor-ligand binding (R-
LB), immunohistochemistry (IHC), and RT-PCR; and 2) to
correlate DR expression to the in vitro effect of dopamine
agonists on ACTH secretion in cultured tumor corticotroph
pituitary cells and to the in vivo effect of cabergoline treat-
ment on ACTH and cortisol secretion in patients with Cush-
ing’s disease (CD), characterized by excessive endogenous
ACTH and cortisol secretion induced by a corticotroph pi-
tuitary tumor (17).
Abbreviations: CD, Cushing’s disease; DR, dopamine receptor;
HPRT, hypoxanthine ribosyl transferase; IHC, immunohistochemistry;
LiDS, lithium dodecyl sulfate; NS, nonspecific; oligo(dT)25, oligo(de-
oxythymidine)25; poly(A)
, polyadenylated; PRL, prolactin; R-LB, re-
ceptor-ligand binding; T, total; TBS-T, Tris-buffered saline-Tween;
WGA, wheat-germ agglutinin.
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Subjects and Methods
Patients
Twenty patients (16 women and 4 men, 25–60 yr of age) with a
diagnosis of CD entered the study after their informed consent had been
obtained. Ten patients were admitted to Department of Internal Med-
icine, Erasmus Medical Center (Rotterdam, The Netherlands; group 1),
and 10 were admitted to Department of Molecular and Clinical Endo-
crinology and Oncology, Federico II University (Naples, Italy; group 2)
over a period of 2 yr. The patients of group 1 were retrospectively
selected on the basis of the availability of a tumor specimen collected and
frozen at the time of neurosurgery; the patients of group 2 were selected
on the basis of the presence of persistent or recurrent disease after
neurosurgery for inclusion in a prospective study. The diagnosis of CD
was based on 1) increase in daily urinary cortisol excretion with inap-
propriately high plasma ACTH concentrations; 2) increase in basal se-
rum cortisol concentrations with lack of the physiological circadian
rhythm; 3) failure of urinary and serum cortisol suppression after low
dose, but greater than 50% decrease after high dose oral dexamethasone
suppression test or a decrease in serum cortisol of at least 7 g/dl in the
7-h continuous iv dexamethasone suppression test (18–20). The diag-
nosis of CD was supported by the evidence of a pituitary tumor at
magnetic resonance imaging of pituitary gland or at bilateral inferior
petrosal sinus sampling (20, 21). Indeed, five of the 20 patients had
pituitarymacroadenoma, 10 hadmicroadenoma, and the remaining five
patients had normal pituitaries; the pituitary source of ACTH hyper-
secretion in these five patients was confirmed by bilateral inferior petro-
sal sinus sampling. All patients were subjected to neurosurgical oper-
ation by the transsphenoidal approach for the removal of the pituitary
tumor. The histological and immunohistochemical study of the tumor
removed by neurosurgery documented a corticotroph pituitary lesion
(adenoma or hyperplasia) in all cases, definitely confirming the diag-
nosis of CD in the totality of patients. After neurosurgery, clinical,
hormonal, and radiological remission of CD was documented in 12
patients, whereas disease persisted in the remaining eight patients.
Moreover, disease recurrence occurred in six of the 12 remitted patients
in the study 1–3 yr after neurosurgery. The patients’ profiles are shown
in Table 1.
Samples
Pituitary tumor specimens were obtained at the time of tumor exci-
sion by neurosurgery. Samples of these specimens were taken fresh
directly at the operation. They were fixed in 10% paraformaldehyde
overnight and embedded in paraffin for the IHC study and/or quickly
frozen on dry ice and stored in a freezer at 80 C for R-LB and/or
RT-PCR studies. In selected cases, a sample was also used for the es-
tablishment of a pituitary tumor primary culture. The study included
only samples in which the tumor tissue represented at least 90% of the
section at the histological evaluation to exclude the influence of normal
pituitary tissue on the results of the studies.
Study design
The study protocol was diversified in the two different groups of
patients. In group 1, D2 receptor expression was evaluated by R-LB and
IHC studies. DR subtype expression was evaluated by RT-PCR in five
of 10 cases. In group 2, D2 receptor expression evaluated by IHC was
correlated to the in vitro effect of dopamine agonists (bromocriptine and
cabergoline) on ACTH secretion and to the in vivo effect of 3-month
cabergoline treatment on cortisol secretion. DR subtype expression was
evaluated by RT-PCR in seven of 10 cases and also correlated to the
results of the in vitro and in vivo functional studies. The protocol was in
accordance with the Helsinki Doctrine on Human Experimentation, and
it was approved by the local Ethics Committees.
R-LB
The R-LB study was performed on tissue samples as previously
reported (22). The frozen tissue samples were cut in 10-m-thick sec-
tions. These sections were mounted onto precleaned, gelatin-coated
microscope glass slides and stored in a freezer at 80 C for at least 3 d
before the experiment to improve adhesion of the tissue to the slide. The
D2 analog [
125I]epidepride (Radiopharmaka, Seibersdorf, Austria) was
used as radioligand. The sections were preincubated at room temper-
ature for 10 min in binding buffer [50 mm Tris-HCl (pH 7.7), 120 mm
NaCl, 5 mm KCl, 2 mm CaCl2 2H2O, 1 mm MgCl2 6H2O, and 0.1%
ascorbic acid]. Thereafter, they were incubated for 60 min at room
temperature in binding buffer with [125I]epidepride. Nonspecific bind-
ing was determined in a sequential section in the presence of excess
unlabeled cabergoline (1 m). A sample was considered positive for
[125I]epidepride binding when the signal was displaced by more than
50%. The incubated sections were washed twice for 5 min each time in
binding buffer. After a short wash in distilled water to remove salts, the
sections were air-dried and exposed to Kodak Biomax film (Eastman
Kodak, Rochester, NY) or HyperFilm-3H (Amersham Pharmacia Bio-
tech, Houten, The Netherlands) for 7–15 and 30–60 d, respectively, in
x-ray cassettes. Histological evaluation was performed on hematoxylin-
eosin-stained sequential cryostat sections. In addition, a positive control,
represented by a sample of rat brain cut at the level of the basal ganglia,
and negative controls, represented by rat tissues known to have no
expression of DRs, were used in each experiment. The binding signals
obtained were analyzed densitometrically using a computer-assisted
image-processing system and were quantified by calculating the ratios
between the regions of interest delineated on the total (T) and nonspe-
cific (NS) binding sections. Using the T/NS ratios, the amount of binding
in every section was graded as negative (), for T/NS ranging from
0–1.9, moderately positive () for T/NS ranging from 2–3, and strongly
positive (2) for T/NS greater than 3.
IHC
The IHC study was performed on tissue samples according to a
previous report (23). The formalin-fixed and paraffin-embedded tissue
samples were cut into 5-m-thick sections. These sections were depar-
affinized, dehydrated, exposed tomicrowave heating in citric acid buffer
at 100 C for 15 min, rinsed in tap water, followed by PBS, and subse-
quently incubated for 15 min in normal goat serum (1:10 dilution in PBS
and 5% BSA). The sections were then incubated overnight at 4 C with
rabbit antihuman D2 receptor polyclonal antibody (Chemicon Interna-
tional, Temecula, CA) in a dilution of 1:500. A standard streptavidin-
biotinylated alkaline phosphatase or -peroxidase complex (ABC kit,
Biogenix, San Ramon, CA) was used to visualize the bound antibodies.
Negative controls for the IHC included 1) omission of the primary
antibody; and 2) preabsorption of the antibodies with the respective
immunizing receptor peptides (at a concentration of 100 nm), both
performed in sequential sections. Immunostaining for ACTH and PRL
as well as GH, TSH, FSH, and LH was also performed on sequential
sections using specific antibodies at the standard dilution. Histological
evaluation was performed on hematoxylin-eosin-stained sequential sec-
tions. Positive and negative controls were represented by D2 receptor
immunostaining on sections of dopamine agonist-sensitive and -resis-
tant, PRL-secreting pituitary tumors, respectively and were carried out
in the same experiments of the corticotroph pituitary tumors. The spec-
ificity of the D2 receptor antibody was tested by immunoblotting using
a corticotroph pituitary tumor sample.
Immunoblotting
The immunoblotting was performed on tissue samples according to
a previous report (24). Membranes were extracted from a frozen tissue
sample. The tissue sample was suspended in an ice-cold Tris-buffer [10
mm Tris-HCl (pH 7.6), 5 mm EDTA, 3 mm EGTA, 250 mm sucrose, 1 mm
phenylmethylsulfonylfluoride, 10 g/ml leupeptin, 10 g/ml soybean-
trypsin-inhibitor, and 50 g/ml bacitracin], homogenized with a Poly-
tron homogenizer at 900 rpm for 10 strokes, and then ultracentrifuged
for 1 h at 4 C at 100,000  g. Membrane pellet was solubilized in a lysis
buffer [20 mmHEPES (pH 7.4), 5 mm EDTA, 3 mm EGTA, 150 mmNaCl,
and 4 mg/ml dodecyl-B-d-maltoside] for 1 h at 4 C and then ultracen-
trifuged at 100,000 g for 1 h at 4 C. Glycosylated proteinswere purified
from the membrane pellet obtained after high speed centrifugation, by
wheat-germ agglutinin (WGA) affinity chromatography: the pellet was
resuspended in lysis buffer and cycled twice over a 0.5-mlWGA (Vector
Laboratories, Inc., Burlingame, CA) column equilibrated with lysis
buffer. The column was washed and eluted with lysis buffer containing
3 mmN,N,Ntriacetyl-chitotriose (Sigma-Aldrich Corp., St. Louis, MO).
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The protein-containing fractions were determined with the Bradford
assay standardized with BSA, pooled, and stored at 80 C. Starting
material and WGA-purified membranes proteins were denatured and
fractionated under reducing conditions on 12.5% SDS-PAGE, then trans-
ferred electrophoretically to Hybond C-Extra nitrocellulose membranes
(Amersham Pharmacia Biotech, Oakville, Canada). After transfer, non-
specific binding sites were blocked by Tris-buffered saline-Tween
(TBS-T) containing 5% nonfat dried milk. After five washes with TBS-T,
membranes were incubated for 16 h at 4 C with a 1:500 dilution of rabbit
antihuman D2 receptor polyclonal antibody (Chemicon International) in
TBS-T containing 1% BSA. Membranes were washed five times with
TBS-T, then incubated for 1 h at 22 C with 1:1000 dilution of horseradish
peroxidase-linked antirabbit IgG (Amersham Pharmacia Biotech) and
again washed. The specificity of the antibody was confirmed by pre-
incubating the antibody with the respective immunizing receptor pep-
tide (at a concentration of 100 nm). Immunoreactive bandswere detected
by the chemiluminescence detection system (ECLWestern blot analysis
system, Amersham Pharmacia Biotech, Little Chalfont, UK). The im-
munoreactive bands were visualized by autoradiography after 0.5-min
exposure to Biomax film (Eastman Kodak Co.). As the antibody recog-
nizes both the native and the denatured forms of D2 receptor, bands of
110, 68, and 47 kDa could be visualized by Western blot. The expected
band with the procedure used in our laboratory was the 68-kDa dena-
tured form.
RT-PCR
mRNA isolation and cDNA synthesis were carried out according to
a previous report (22). mRNA was isolated using Dynabeads oligo(de-
oxythymidine)25 [oligo(dT)25; Dynal AS, Oslo, Norway] from a frozen
tissue sample. The cells were lysed for 2 min in ice-cold Tris buffer [100
mm Tris-HCl (pH 8), 500 mm LiCl, 10 mm EDTA, 1% lithium dodecyl
sulfate (LiDS), 5mmdithiothreitol, and 5U/100l ribonuclease inhibitor
(HT Biotechnology Ltd., Cambridge, UK)]. Themixture was centrifuged
at 14,000 rpm for 1 min to remove cell debris. After adding 100 l
prewashed Dynabeads oligo(dT)25 to the supernatant, the mixture was
incubated for 5 min on ice. Thereafter, the beads were collected with a
magnet and washed three times with Tris buffer [10 mm Tris-HCl (pH
8), 0.15 m LiCl, 1 mm EDTA, and 0.1% LiDS] and once with a similar
buffer fromwhich LiDS was omitted. mRNAwas eluted from the beads
in 50 ml of a 2 mm EDTA solution (pH 8) during 2 min at 65 C. To avoid
contamination by genomic DNA, the isolated polyadenylated
[poly(A)] mRNA was subjected to a second purification by capturing
the RNA on a fresh aliquot of prewashed Dynabeads oligo(dT)25 and
washing the captured RNA as described above. cDNA was synthesized
using the poly(A) mRNA captured on the Dynabeads oligo(dT)25 in
Tris buffer [50 mm Tris-HCl (pH 8.3), 100 mm KCl, 4 mm dithiothreitol,
and 10 mmMgCl2] together with 1 mm of each deoxynucleotide triphos-
phate, 10 U ribonuclease inhibitor, and 2 U avian myeloblastosis virus
Super Reverse Transcriptase (HT Biotechnology Ltd.) in a final volume
of 20 l. This mixture was incubated for 1 h at 42 C. One tenth from each
cDNA library immobilized on the paramagnetic beadswas used for each
amplification. The amplification reaction mixture contained cDNA tem-
plate, 0.5 U SuperTaq (HT Biotechnology Ltd.), 50 m of each de-
oxynucleotide triphosphate (HT Biotechnology Ltd.), 5 pmol of each of
a pair of oligonucleotide primers specific for human D1–D5 receptor
subtypes or the hypoxanthine ribosyl transferase (HPRT) in Tris buffer
[10 mm Tris-HCl (pH 9), 50 mm KCl, 2 mm MgCl2, 0.01% (wt/vol)
gelatin, and 0.1% Triton X-100 in a final volume of 50 l]. The sequences
of the primers for D1–D5 and HPRT are listed in Table 2. The PCR
reaction was carried out in a DNA thermal cycler (PerkinElmer/Cetus,
Gouda, The Netherlands). After an initial denaturation at 94 C for 5 min,
the samples were subjected to 40 cycles of denaturation at 94 C for 1min,
annealing for 2 min at 60 C, and extension for 1 min at 72 C. After a final
extension for 10min at 72 C, 10-l aliquots of the resulting PCR products
were analyzed by electrophoresis on 1.5% agarose gels stained with
ethidium bromide. Several controls were included in the RT-PCR ex-
periments. To ascertain that no detectable genomic DNAwas present in
the poly(A)mRNApreparation for twoDR subtypes, D1 andD5,whose
genes are intron-less, the cDNA reactions were also performed without
reverse transcriptase and amplifiedwith each primer pair. Amplification
of the cDNA samples with the HPRT-specific primers served as a pos-
itive control for the quality of cDNA. To exclude contamination of the
PCR reactionmixtures, the reactions were also performed in the absence
of DNA template in parallel with cDNA samples. As a positive control
for the PCR reactions of the DR subtypes and HPRT, 0.01 g human
brain cDNA was amplified in parallel with the cDNA samples of each
examined pituitary corticotroph tumor.
In vitro functional study
The cell culture was performed according to a previous report (25).
Tumor tissue samples were placed in HBSS (Life Technologies, Inc.,
Paisley, UK), supplemented with 5% human serum albumin (Cealb,
CLB, Amsterdam, The Netherlands), penicillin (105 U/liter), and fun-
gizone (0.5 mg/liter). After careful removal of blood clots, the samples
wereminced andwashed several timeswith theHBSS andhuman serum
albumin. The minced tissues were enzymatically dissociated with dis-
pase (1000 U/liter) for 1–2 h at 37 C. After removal of erythrocytes by
centrifugation on a Ficoll gradient, the tumor pituitary cells were plated
in 24-well plates (Costar, Cambridge, MA) in 1 ml DMEM (Life Tech-
nologies, Inc.) culturemedium containing 10% (vol/vol) fetal calf serum
and penicillin/streptomycin andwere incubated at 37 C in a humid CO2
incubator for 24–48 h to allow them to attach at the bottom of the plate
wells. Then, mediumwas removed and replaced with 1ml fresh DMEM
culturemedium, test substanceswere added, and cells were reincubated
at 37 C for 72 h. Afterward, medium was collected and stored at 20 C
for the measurement of ACTH secretion. In all experiments, bromocrip-
tine and cabergoline were used as test substances and were added to the
cell cultures at concentrations of 0, 1012, 1010, 109, 108, and 106 m.
In two cases (no. 5 and 8), the specificity of the drug effect was tested
coincubating the D2 agonist with an excess (10 m) of the D2 antagonist
sulpiride.
TABLE 2. Specific oligonucleotide primers for DR subtypes (D1–D5) and controls used in the RT-PCR study
Gene Sequence (5–3) Size of PCR product (bp)
Dopamine receptors
D1 Forward AACACCTCTGCCATGGACG 616
Reverse TGATGGCCACAGGGATGTAA
D2 Forward GCGGACAGACCCCACTACAA 521
Reverse AAGGGCACGTAGAAGGAGAC
D2 short/long isoforms Forward CCATGCTGTACAATACGCGCT D2 long:599;D2 short:512
Reverse GGCAATCTTGGGGTGGTCTTT
D3 Forward CCCGCCCACATGCCTACTAT 1106
Reverse GAAGGCTTTCCGGAACTCGAT
D4 Forward CCCACCCCAGACTCCACC 259
Reverse GAACTCGGCGTTGAAGACAG
D5 Forward ACCTGTGCGTCATCAGCGT 921
Reverse TGCGATCGAAAGGACCCTC
HPRT Forward CAGGACTGAACGTCTTGCTC 413
Reverse CAAATCCAACAAAGTCTGGCT
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In vivo functional study
The patients were treated with cabergoline. Cabergoline was admin-
istered at an initial dose of 1mg/wkwith amonthly increase of 1mg/wk
until normalization of daily urinary cortisol excretion. Plasma ACTH
and serum and urinary cortisol levels after 3 months of treatment were
compared with the baseline hormonal values. The mean of three dif-
ferent measurements of these hormones on 3 nonconsecutive d of the
same week were considered for the baseline and posttreatment evalu-
ations. During cabergoline treatment, blood and urinary samples were
collected on the days when the patients did not take the drug. A 50% or
greater decrease in daily urinary cortisol excretion was considered a
significant clinical response to cabergoline. Moreover, patients who
achieved a 50% or greater decrease with normalization of urinary cor-
tisol levels were considered full responders, whereas those who
achieved a 50% or greater decrease without normalization of urinary
cortisol levels were considered partial responders to cabergoline. Pa-
tients who achieved less than a 50% decrease in urinary cortisol levels
were considered resistant to cabergoline treatment. After 3 months of
treatment, two patients were taking 1 mg, three were taking 2 mg, and
the remaining five were taking 3 mg/wk cabergoline.
Hormonal assays
ACTH levels were measured by immunoradiometric assay using a
commercially available kit. Serum and urinary cortisol levels were mea-
sured by radioimmunological assay, using commercially available kits.
Statistical analysis
Data are expressed as the mean  se. The comparison between post-
and pretreatment hormone values was made using ANOVA, followed
by Newman-Keuls test. The association between parameters was cal-
culated by 2 test. Significance was set at 5%.
Results
Histological evaluation and IHC for pituitary hormones
Basophilic adenoma was documented in 12 (60%), baso-
philic hyperplasia in three (15%), chromofobe adenoma in
four (20%), and acidophilic adenoma in one (5%) case. Pos-
itive immunostaining for ACTH was documented in all 20
cases (100%) in correspondence with the adenomatous or
hyperplasic tissue. Conversely, positive immunostaining for
PRL was documented in 13 (65%) cases. However, PRL im-
munostaining was positive in scattered normal cells (acido-
philic ACTH-negative cells) within the tumor tissue in six
(30%), in defined areas of normal cells within or around the
tumor tissue in four (20%), and in defined areas of tumor
tissue (basophilic ACTH-positive cells) in two (10%) cases.
The remaining case was characterized by diffuse PRL im-
munostaining covering all acidophilic ACTH-positive tumor
tissues. This case was diagnosed as a mixed ACTH/PRL-
secreting pituitary tumor. No significant immunoreactivity
was found for GH, TSH, FSH, and LH in all cases; this was
only represented by scattered cells around the tumor tissue,
probably belonging to contaminating normal pituitary. The
histological and immunohistochemical features for pituitary
hormones of the tumor samples are listed in Tables 3 and 4
for groups 1 and 2, respectively.
R-LB study
Specific binding of [123I]epidepride was found at autora-
diography in eight of 10 (80%) cases in group 1. It was
localized in tumor cells and in normal scattered cells or
defined areas around tumor tissue or within normal pitu-
itary. The binding was homogeneously distributed in four
(50%) and not homogeneously distributed within the tumor
tissue in the remaining four (50%) cases. It was scored as
moderately positive in three (37.5%) and strongly positive in
the remaining five (62.5%) positive cases. The results of the
R-LB study are summarized in Table 3. An example of a
negative and a positive autoradiography of [125I]epidepride
binding are shown in Fig. 1.
Immunoblotting
A specific band of the expected molecular weight (68 kDa)
of D2 receptor was found at the immunoblot of glycoproteins
derived from a corticotroph pituitary tumor (Fig. 2).
IHC for D2 receptor
Specific immunoreactivity for D2 receptor was found in 15
(75%) cases, eight (80%) in group 1 and seven (70%) in group
2. It was localized in ACTH- andACTH/PRL-positive tumor
cells and in normal PRL-positive cells or areas localized
around tumor tissue or within pituitary. The immunoreac-
tivity was homogeneously distributed in seven (46.7%) and
was not homogeneously distributed within the tumor tissue
in eight (53.3) cases. It was scored as moderately positive in
eight (53.3%) and strongly positive in the remaining seven
(46.7%) positive cases. In group 1, a complete correspon-
dence was found between the results of R-LB and the IHC
studies. The results of IHC are summarized in Tables 3 and
4 for groups 1 and 2, respectively. Examples of a negative and
TABLE 3. DR expression in corticotroph pituitary tumors of patients of group 1
Patient
no. R-LB Study
IHC RT-PCR study
Histology ACTH PRL D2 D1 D2 D2s/1 D3 D4 D5 HPRT
1  Basophilic hyperplasia      Long    
2  Basophilic adenoma    NE NE NE NE NE NE NE
3  Chromofobe adenoma    NE NE NE NE NE NE NE
4  Chromofobe adenoma    NE NE NE NE NE NE NE
5  Basophilic adenoma    NE NE NE NE NE NE NE
6  Basophilic adenoma      Short    
7  Basophilic adenoma      Long/Short    
8  Basophilic hyperplasia          
9  Basophilic adenoma    NE NE NE NE NE NE NE
10  Basophilic adenoma      Long/Short    
, Strongly positive; , weakly positive; , negative; NE, not evaluated.
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a positive immunostaining for D2 receptor are shown in
Fig. 3.
RT-PCR study
D2 receptor was expressed in 10 of 12 cases (83.3%). D2long
was found in four (40%), D2short in two (20%), and both D2
isoforms in four (40%) positive cases. D4 receptor was ex-
pressed in two cases (20%) associated with the expression of
D2long in one and with both D2 isoforms in the remaining
case. A complete correspondence was found between the
results of RT-PCR and those of R-LB and IHC studies. No
expression of other DRs were found. The results of the RT-
PCR study are summarized in Tables 3 and 4 for groups 1 and
2, respectively.
In vitro functional study
A significant and dose-dependent inhibition of ACTH se-
cretion was found in two of four cases (50%) in group 2 after
both bromocriptine and cabergoline administration. The in-
hibition rate was 43% in the first case and 52% in the second
one after bromocriptine treatment, and 53% in the first case
and 60% in the second one after cabergoline administration,
respectively. Both cases (100%) had documented expression
of D2 receptor. No significant inhibition of ACTH secretion
was found in the remaining two cases after either bromocrip-
tine or cabergoline administration. The inhibition rates were
12% and 15% after bromocriptine and 13% and 14% after
cabergoline administration for the two cases, respectively.
TABLE 4. DR expression in corticotroph pituitary tumors of patients of group 2
Patient
no.
IHC RT-PCR study In vitro ACTH secretioninhibition (%)
Histology ACTH PRL D2 D1 D2 D2s/1 D3 D4 D5 HPRT After
bromocriptine
After
cabergoline
1 Basophilic adenoma      Long     NE NE
2 Chromofobe adenoma           12 13
3 Basophilic adenoma      Short     NE NE
4 Acidophilic adenoma      Long/Short     43 57
5 Basophilic adenoma    NE NE NE NE NE NE NE 15 14
6 Basophilic hyperplasia    NE NE NE NE NE NE NE NE NE
7 Basophilic adenoma      Long     NE NE
8 Chromofobe adenoma      Long     53 60
9 Basophilic adenoma      Long/Short     NE NE
10 Basophilic adenoma    NE NE NE NE NE NE NE NE NE
, Strongly positive; , weakly positive; , negative; NE, not evaluated.
FIG. 1. Expression of D2 DR subtypes by R-LB study in two
cases of human corticotroph pituitary tumors. Photomicro-
graph of D2 receptor autoradiography. A, Hematoxylin-
eosin-stained section; B, autoradiography showing total
binding of [125I]epidepride; C, autoradiography showing
nonspecific binding (in the presence of 1 M cabergoline).
The picture shows a positive (no. 1, case 2 of Tables 1 and
3) and a negative (no. 2, case 8 of Tables 1 and 3) case. The
specificity of binding is demonstrated by the complete dis-
appearance of the radioactive signal in the presence of an
excess of the high affinity D2 agonist cabergoline.
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No D2 expression was found in either case (100%). The spec-
ificity of the effects of bromocriptine and cabergoline was
demonstrated by the block of this effect in one responsive
case by the D2 antagonist sulpiride (no. 8). No significant
effect of sulpiride was demonstrated in one nonresponsive
case (no. 5). The results of the in vitro study are summarized
in Table 4. The individual ACTH responses to bromocriptine
and cabergoline in all four corticotroph pituitary tumor cul-
tures are shown in Fig. 4.
In vivo functional study
Significant inhibition of plasma ACTH and serum and
urinary cortisol levels after 3 months of cabergoline treat-
ment was found in six of 10 (60%) cases in group 1. However,
normalization of urinary cortisol was found in four of 10
(40%) cases, who were considered full responders, whereas
a significant decrease without normalization of urinary cor-
tisol was found in the remaining two cases, who were con-
sidered partial responders. A significantly different decrease
in urinary cortisol levels was found between responder and
resistant patients who did not achieve a 50% or greater de-
crease in urinary cortisol levels after 3 months of cabergoline
treatment (79.7  3.6% vs. 27.7  7.8%; P  0.05). All cases
responsive to cabergoline were associated with D2 expres-
sion in the tumor tissue. Conversely, all cases not responsive
to cabergoline were not associated with D2 expression, with
the exception of one case (no. 6 in Tables 1 and 4), which was
associated with a poor response to cabergoline treatment. A
trend for a significant association betweenD2 expression and
clinical response to cabergoline (2 3.35; P  0.067) was
found in the patients in this study. Among the four cases in
which a normalization of ACTH and cortisol was obtained,
three expressed D2short, which was isolated in one case and
associated with D2long in the remaining two cases. The third
case was associatedwith the expression of D2long andD4. The
remaining case with a significant in vivo response to caber-
goline and the only case not responsive to cabergoline, but
D2 positive, expressed D2long, but not D2short or D4, receptors.
The individual responses of urinary cortisol levels to the
3-month treatmentwith cabergoline are shown in Figs. 5 and 6.
Discussion
The current study clearly demonstrated D2 receptor ex-
pression in corticotroph pituitary tumors and the effective-
ness of cabergoline treatment in controlling the cortisol hy-
persecretion associated with CD.
CD is a severe chronic disorder resulting from inappro-
priate and prolonged exposure to excessive endogenous ad-
renal cortisol secretion secondary to altered pituitary ACTH
secretion due to corticotroph pituitary tumor (17); it repre-
sents the most common form of chronic endogenous hyper-
cortisolism, accounting for about 80% of cases of Cushing’s
syndrome (17). Neurosurgical resection of the pituitary tu-
mor is the first-line treatment of CD (26). However, trans-
sphenoidal neurosurgery is successful in 70–80% of cases
(27, 28). Moreover, neurosurgical outcome is also affected by
the lack of tumor evidence at transsphenoidal exploration in
15% and disease relapse after surgical remission in almost
10% of cases (26–28). Pituitary irradiation and total bilateral
adrenalectomy represent second choice treatments in pa-
tients not cured by neurosurgery (17). However, although
associated with a high success rate, these treatment modal-
ities frequently result in secondary adverse events, such as
hypopituitarism in the former and the development of a large
and invasive pituitary tumor in the latter. In addition, ad-
renal insufficiency makes the patient life-long dependent on
daily administration of glucocorticoids and mineralocorti-
coids (17). Medical treatment presently plays a minor role in
the treatment of CD; it is usually performed before neuro-
surgery or after pituitary irradiation to obtain rapid hor-
monal normalization before the definitive cure (16). Medical
treatment is usually performed with adrenal-blocking drugs
that do not act at level of the pituitary tumor (16). On the
other hand, although several neuromodulatory drugs acting
at the pituitary level have been used in the treatment of CD,
no single agent has ever demonstrated sufficient effective-
ness to achieve widespread clinical use in the management
of the disease (29–31).
The only neuromodulatory drug that had a relevant, al-
though controversial, role in the treatment of CD was bro-
mocriptine, the most widely used dopamine agonist. Bro-
mocriptine was hypothesized to induce inhibition of ACTH
secretion and/or cell growth in corticotroph pituitary tu-
mors, acting through DRs presumably expressed in the
pituitary tumor cells. This hypothesis was based on the
evidence that DRs with an inhibitory function were demon-
strated to be expressed in PRL-secreting pituitary tumors,
where they induced a suppression of hormone secretion and
inhibition of tumor growth in a greatmajority of cases (7–13).
In corticotrophpituitary tumors, bromocriptinewas found to
induce significant inhibition or normalization of cortisol se-
cretion in about 40% of cases after short-term treatment (32).
However, controversial results with a success rate ranging
from 0–50% were obtained by the different studies that
tested the effectiveness of bromocriptine treatment in CD
(16). Moreover, normalization of cortisol secretion and/or
tumor shrinkage were only sporadically reported after long-
FIG. 2. Immunoblot of glycoproteins derived from a human cortico-
troph pituitary tumor with D2 receptor antibody. A and B, Cortico-
troph pituitary tumor without (A) and with (B) preincubation of the
antibody with the antigen. The specificity of the immunoblot is dem-
onstrated by the complete disappearance of the signal after preincu-
bation of the antibody with the antigen (D2 receptor peptide).
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term treatment with bromocriptine, demonstrating that only
a subset of patients with CD was able to respond to chronic
bromocriptine treatment (16, 33, 34). On the other hand,
cabergoline was reported to induce significant shrinkage of
a silent ACTH-secreting pituitary tumor (35), and a func-
tioning ACTH-secreting pituitary tumor developed after bi-
lateral adrenalectomy in a patient cured from CD (36). How-
ever, no study has ever evaluated the effectiveness of
cabergoline treatment inCD. The current study evaluated the
effectiveness of short-term treatment with cabergoline in a
group of patients with CD, demonstrating significant inhi-
bition of cortisol secretion in 60% and normalization of cor-
tisol secretion in 40% of cases, suggesting that cabergoline is
more effective than bromocriptine and is potentially useful
in the treatment of CD.
The biological basis of the effectiveness of dopamine ago-
nists in the treatment of pituitary tumors is represented by
DR expression in the tumor. In the pituitary, the response to
dopamine agonists is related to the activity of the D2 receptor
(37, 38). This receptor belongs to the family of G protein-
coupled receptors and acts through AMP cyclase enzyme
inhibition (1, 39). Alternative splicing of the gene encoding
D2 receptor leads to twodifferent isoforms: the short isoform,
named D2short, and the long isoform, named D2long (1, 40). In
normal human pituitary, D2 receptor has been demonstrated
to be expressed in more than 75% of the cell population,
indicating that D2 receptors are not expressed only in lac-
totrophs and melanotrophs, which represent no more than
30% of the entire cell population of the normal pituitary
gland (37). However, no study has systematically evaluated
the colocalization of D2 receptor with the different pituitary
hormones in normal human pituitary gland, leaving only as
a likely hypothesis the possible expression of D2 receptor in
non-PRL- and non-MSH-secreting normal pituitary cells. A
FIG. 3. Expression of D2 receptor by immu-
nohistochemistry in two cases of human
corticotroph pituitary tumors. The immu-
nohistochemical study has been performed
on formalin-fixed and paraffin-embedded
sections of the tumors. A, Hematoxylin-
eosin-stained section; B, ACTH immuno-
staining; C, PRL immunostaining; D, D2
receptor immunostaining performed with a
specific polyclonal D2 receptor antibody; E,
D2 receptor immunostaining after preincu-
bation of the antibody with the specific an-
tigen. The picture shows a D2 receptor-pos-
itive (no. 1, case 7 of Tables 1 and 4) and a
negative (no. 2, case 5 of Tables 1 and4) case
of ACTH-positive basophilic adenoma.
ACTH immunostaining is similar in all
cases, whereas PRL immunostaining shows
a variable pattern in the different cases. In
this figure, PRL immunostaining is nega-
tive and scattered positive in cases 1 and 2,
respectively. The immunostaining for D2
receptor shows a homogeneous distribution
in half and a dishomogeneous distribution
within tumor tissue in the remaining half of
the cases. In this figure, it was homoge-
neously positive and negative in cases 1 and
2, respectively. The specificity of the immu-
nostaining is demonstrated by the disap-
pearance of colorimetric signal after preab-
sorption of the antibody with 100 nM
specific antigen (D2 receptor peptide). Mag-
nification, 40.
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variable and heterogeneous expression of D2 receptor has
been recently demonstrated by in situ hybridization and IHC
in 89% of all types of pituitary tumors, and particularly in
69% of silent or functioning ACTH-secreting pituitary tu-
mors (41). In PRL-secreting pituitary tumors, the presence of
a large amount of D2 receptor explains the good therapeutic
response to dopamine agonists, which induces PRL secretion
inhibition and tumor shrinkage (42). Moreover, cabergoline
has been clearly demonstrated to be more effective than
bromocriptine in the treatment of this type of tumor (14, 15).
Resistance to dopamine agonists in PRL-secreting pituitary
tumor may be explained by the absence or a small amount of
D2 receptor or its functional inactivity (43). D2 receptor has also
been demonstrated in GH-secreting pituitary tumors (44), al-
though their response to dopamine agonists is not as marked
FIG. 4. Effect of in vitro administration of bromocriptine () and cabergoline (f) on ACTH secretion in cell cultures derived by four different
corticotroph pituitary tumors [cases 4 (A), 8 (B), 2 (C), and 5 (D) of Tables 1 and 4]. Corticotroph pituitary tumor cells were incubated in DMEM
supplemented with 10% fetal calf serum and penicillin/streptomycin for 72 h in quadruplicate without (C) or with the drugs at concentrations
of 1012, 1010, 109, 108, and 106 M and in two cases (no. 5 and 8) with the drug at a dose of 1 M coincubated with an excess (10 M) of
the D2 antagonist sulpiride (S). Values are expressed as the percentage secretion and are the mean  SEM (n  4/treatment group).
FIG. 5. Effect of in vivo administration of cabergoline on urinary
cortisol secretion in the 10 patients of group 2. Cabergoline was
administered at an initial dose of 1mg/wk in all patients and at a final
dose ranging from 1–3 mg/wk after 3 months of treatment. The dose
was increased monthly by 1 mg/wk every month until normalization
of urinary cortisol excretion. Daily urinary cortisol is expressed as
absolute values in micrograms per day.
FIG. 6. Individual values of urinary cortisol levels at baseline and
during the 3 months of cabergoline treatment of the 10 patients of
group 2. Cabergoline was administered at an initial dose of 1 mg/wk
in all patients and at a final dose ranging from 1–3 mg/wk after 3
months of treatment. The dose was increased monthly by 1 mg/wk
until normalization of urinary cortisol excretion. Daily urinary cor-
tisol is expressed as absolute values in micrograms per day.
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as in PRL-secreting pituitary tumors, probably due to a differ-
ence in the abundance or functionality of the receptor (32, 45).
However, the relative resistance of these tumors to dopamine
agonistswas found tobeovercome inapercentageof caseswith
the use of cabergoline (46, 47). In clinically nonfunctioning pi-
tuitary tumors, D2 receptor has been demonstrated in a large
number of cases (48, 49), although tumor shrinkage has been
reported in only aminority (34, 50). However, in a recent study
cabergoline was demonstrated to be more effective than bro-
mocriptine at inducing tumor shrinkage (51). Dopamine ago-
nist resistance in these tumors may be due to the same D2
receptor abnormalities observed in PRL- and GH-secreting pi-
tuitary tumors. However, the expression of D2short, rather than
D2long, has been suggested to be associatedwith a better in vitro
response to dopamine agonists (52).
As far as corticotroph pituitary tumors are concerned, no
definitive evidence is available on D2 receptor expression, as
one study demonstrated the absence of a significant and
specific binding of radiolabeled spiperone, a dopamine an-
tagonist, in two corticotroph pituitary tumors (8), whereas
another study more recently demonstrated D2 receptor ex-
pression by in situ hybridization and IHC studies (41). How-
ever, experimental evidence in humans and rats supports the
hypothesis of D2 receptor expression and function in corti-
cotroph pituitary tumors. Indeed, bromocriptine was dem-
onstrated to suppress ACTH secretion from cultured human
pituitary tumor cells by a dopaminergic mechanism (53) and
to induce apoptosis in AtT-20 cells, a murine corticotroph
pituitary tumor cell line (54). The current study represents
the first clear demonstration of both D2 receptor expression
and D2 receptor function in corticotroph pituitary tumors.
This finding is strongly supported by the following evidence.
1) D2 receptor expression has been evaluated at a molecular
and cellular levels by different techniques, which permitted
demonstration of both transcription of D2 receptor gene and
translation in a D2 receptor protein. 2) The comparison be-
tween the images obtained by R-LB or IHC studies and the
histology results clearly demonstrated the presence of D2
receptors in tumor cell cytoplasm or membranes, excluding
that the D2 receptor demonstrated at a molecular level might
exclusively belong to normal pituitary cell infiltration within
or normal pituitary tissue surrounding tumor tissue. 3) The
in vitro effect of dopamine agonists on ACTH secretion in-
hibition in cell cultures obtained by D2 positive-corticotroph
pituitary tumor samples and the lack of this effect in cell
cultures obtained by D2-negative corticotroph pituitary tu-
mor samples demonstrated the expression of a functional D2
receptor mediating the effect of dopamine agonists in these
tumors. 4) The in vivo effect of cabergoline on cortisol secre-
tion inhibition only in CD patients with corticotroph pitu-
itary tumors expressingD2 receptor definitely confirmed that
D2 receptor may mediate an important effect of dopamine
agonists on ACTH and, consequently, cortisol secretion in
corticotroph pituitary tumors.
The results of the current study support a possible ther-
apeutic role of dopamine agonists in the treatment of CD. The
expression of D2 receptor in 80% of corticotroph pituitary
tumors and the effectiveness of cabergoline treatment in 60%,
with normalization of cortisol secretion in 40%, of patients
with CD justify the possible use of cabergoline for controlling
ACTH and cortisol hypersecretion associated with CD. The
different successful rates observed with bromocriptine in
past studies and with cabergoline in the present study may
be related to the different molecular, biochemical, and phar-
macological characteristics of the two dopamine agonists,
particularly to the higher specificity and affinity for D2 re-
ceptor and the longer duration of action of cabergoline than
bromocriptine (55, 56). The evidence of a similar in vitro effect
of bromocriptine and cabergoline in the four cases included
in the study does not allow us to draw definitive conclusions
about the in vitro effects of the two drugs in corticotroph
pituitary tumors due to the small number of cases evaluated.
Moreover, different in vitro and in vivo behaviors of the two
drugs could be also not surprising, considering that the in
vivo effect of any drug is influenced by several factors that
cannot be completely foreseen and reproduced in in vitro
studies. Finally, it should be mentioned that the CD patients
included in the current study were selected from two dif-
ferent endocrine clinics on the basis of the availability of
tumor tissue, which excluded the smallest tumors, or on the
basis of failure of neurosurgery with consequent persistence
of CD and/or recurrence of CD, which mainly included the
tumors not easily removable by neurosurgery. In this view,
the data presented in the current study do not necessarily rep-
resent the whole population of patients with CD. Cabergoline
may be added to the list of therapeutic options and drugs that
can be adopted in different phases and conditions related to a
complex disease such as Cushing’s syndrome (57).
In conclusion, the current study demonstrated the expres-
sion and function of the D2 receptor in corticotroph pituitary
tumors. The presence of a functional D2 receptor in 60% and
the demonstration of effectiveness of a short-term treatment
with the dopamine agonist cabergoline in normalizing
ACTH and cortisol secretion in 40% of corticotroph pituitary
tumors strongly support the possible therapeutic use of this
drug in the management of persistent and/or recurrent CD.
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